{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T22:04:51Z","timestamp":1788818691043,"version":"build-2803163510"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012684","name":"Center for Clinical and Translational Sciences, University of Texas Health Science Center at Houston","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012684","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["1R61NS119640-01A1"],"award-info":[{"award-number":["1R61NS119640-01A1"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01NS131469"],"award-info":[{"award-number":["R01NS131469"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurocrit Care"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Subarachnoid hemorrhage (SAH) causes life-long neurologic dysfunction. Peripheral inflammatory processes as a reaction to brain injury have been shown to worsen outcomes after SAH. Galantamine has been shown to reduce proinflammatory microglial activities and improve synaptic connections. We hypothesize that galantamine treatment after SAH mitigates inflammation-mediated neuronal injury and improve outcomes. We conducted a pilot clinical trial to examine the tolerability and safety of galantamine in patients with SAH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This prospective, multicenter, double-masked, randomized, placebo-controlled study contiguously screened and enrolled adult patients presenting with aneurysmal SAH with a Fisher grade of 3 within 72\u00a0h of symptom onset. A total of 60 patients were enrolled with a 1:1 ratio to two treatment arms. The first 30 patients were randomly assigned to receive galantamine at 8\u00a0mg every 12\u00a0h or a placebo, and the other 30 patients to were randomly assigned to receive either galantamine at 12\u00a0mg every 12\u00a0h or a placebo. All medications were started within 36\u00a0h after securing the aneurysm and continued for 90\u00a0days. Primary outcomes\u2014tolerability as assessed by the number of patients who stop study medication due to adverse events associated with the study drug and mortality due to the study drug\u2014were assessed at 90\u00a0days.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      There were no differences in tolerability and safety between the two groups. Bradycardia was the most common adverse event (37%), followed by clinical seizure (3%) and skin rash (3%). One study participant in the galantamine group discontinued medication due to a skin rash, and another study participant from the placebo group discontinued due to nausea (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.92). Mortality did not differ between the two groups. At 90\u00a0days, one study participant from the galantamine group and four study participants from the placebo group died (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.34).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Galantamine was as tolerable and safe as a placebo based on discontinuation rates and mortality in patients with SAH when administered to patients with SAH during the early and subacute stages of the disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12028-025-02349-3","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T17:10:37Z","timestamp":1756401037000},"page":"986-998","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["SAHRANG: Subarachnoid Hemorrhage Recovery and Galantamine: A Pilot Multicenter Randomized Placebo-Controlled Trial"],"prefix":"10.1007","volume":"43","author":[{"given":"Bosco Seong Kyu","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jude P. J.","family":"Savarraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin E.","family":"Immanuel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgene","family":"Hergenroeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenda","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Hwan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Samuel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Pedroza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James C.","family":"Grotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Barreto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7218-832X","authenticated-orcid":false,"given":"H. Alex","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,28]]},"reference":[{"key":"2349_CR1","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.nec.2009.10.014","volume":"21","author":"AA Le Roux","year":"2010","unstructured":"Le Roux AA, Wallace MC. Outcome and cost of aneurysmal subarachnoid hemorrhage. Neurosurg Clin N Am. 2010;21:235\u201346.","journal-title":"Neurosurg Clin N Am"},{"key":"2349_CR2","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s11910-024-01396-1","volume":"25","author":"BSK Yang","year":"2025","unstructured":"Yang BSK, Gusdon AM, Ren XS, et al. Update on strategies to reduce early brain injury after subarachnoid hemorrhage. Curr Neurol Neurosci Rep. 2025;25:14.","journal-title":"Curr Neurol Neurosci Rep"},{"key":"2349_CR3","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/s12974-019-1578-1","volume":"16","author":"S-H Ahn","year":"2019","unstructured":"Ahn S-H, Savarraj JPJ, Parsha K, et al. Inflammation in delayed ischemia and functional outcomes after subarachnoid hemorrhage. J Neuroinflammation. 2019;16:213.","journal-title":"J Neuroinflammation"},{"key":"2349_CR4","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1007\/s12028-018-0650-5","volume":"32","author":"F Oka","year":"2020","unstructured":"Oka F, Chung DY, Suzuki M, Ayata C. Delayed cerebral ischemia after subarachnoid hemorrhage: experimental-clinical disconnect and the unmet need. Neurocrit Care. 2020;32:238\u201351.","journal-title":"Neurocrit Care"},{"key":"2349_CR5","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1007\/s13311-021-01052-3","volume":"18","author":"A Dienel","year":"2021","unstructured":"Dienel A, Veettil RA, Matsumura K, et al. \u03b17-acetylcholine receptor signaling reduces neuroinflammation after subarachnoid hemorrhage in mice. Neurotherapeutics. 2021;18:1891\u2013904.","journal-title":"Neurotherapeutics"},{"key":"2349_CR6","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1093\/ajhp\/58.8.649a","volume":"58","author":"CA Thompson","year":"2001","unstructured":"Thompson CA. FDA approves galantamine for Alzheimer\u2019s disease. Am J Health Syst Pharm. 2001;58:649\u2013649.","journal-title":"Am J Health Syst Pharm"},{"key":"2349_CR7","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1002\/gps.949","volume":"18","author":"D Aarsland","year":"2003","unstructured":"Aarsland D, Hutchinson M, Larsen JP. Cognitive, psychiatric and motor response to galantamine in Parkinson\u2019s disease with dementia. Int J Geriatr Psychiatry. 2003;18:937\u201341.","journal-title":"Int J Geriatr Psychiatry"},{"key":"2349_CR8","volume":"2","author":"CE Battle","year":"2021","unstructured":"Battle CE, Abdul-Rahim AH, Shenkin SD, Hewitt J, Quinn TJ. Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis. Cochrane Database Syst Rev. 2021;2: CD013306.","journal-title":"Cochrane Database Syst Rev"},{"key":"2349_CR9","doi-asserted-by":"publisher","first-page":"e2220","DOI":"10.1212\/WNL.0000000000011832","volume":"96","author":"H Xu","year":"2021","unstructured":"Xu H, Garcia-Ptacek S, J\u00f6nsson L, Wimo A, Nordstr\u00f6m P, Eriksdotter M. Long-term effects of cholinesterase inhibitors on cognitive decline and mortality. Neurology. 2021;96:e2220\u201330.","journal-title":"Neurology"},{"key":"2349_CR10","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1111\/jnc.15243","volume":"158","author":"CN Metz","year":"2021","unstructured":"Metz CN, Pavlov VA. Treating disorders across the lifespan by modulating cholinergic signaling with galantamine. J Neurochem. 2021;158:1359\u201380.","journal-title":"J Neurochem"},{"key":"2349_CR11","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s12974-018-1141-5","volume":"15","author":"Y Liu","year":"2018","unstructured":"Liu Y, Zhang Y, Zheng X, et al. Galantamine improves cognition, hippocampal inflammation, and synaptic plasticity impairments induced by lipopolysaccharide in mice. J Neuroinflammat. 2018;15:112.","journal-title":"J Neuroinflammat"},{"key":"2349_CR12","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1038\/npp.2015.282","volume":"41","author":"TW McAllister","year":"2016","unstructured":"McAllister TW, Zafonte R, Jain S, et al. Randomized placebo-controlled trial of methylphenidate or galantamine for persistent emotional and cognitive symptoms associated with PTSD and\/or traumatic brain injury. Neuropsychopharmacology. 2016;41:1191\u20138.","journal-title":"Neuropsychopharmacology"},{"key":"2349_CR13","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1136\/jnnp-2012-302268","volume":"83","author":"JM Hong","year":"2012","unstructured":"Hong JM, Shin DH, Lim TS, Lee JS, Huh K. Galantamine administration in chronic post-stroke aphasia. J Neurol Neurosurg Psychiatry. 2012;83:675\u201380.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2349_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i5239","volume":"355","author":"SM Eldridge","year":"2016","unstructured":"Eldridge SM, Chan CL, Campbell MJ, et al. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. BMJ. 2016;355: i5239.","journal-title":"BMJ"},{"key":"2349_CR15","first-page":"21","volume":"59","author":"JA Frontera","year":"2006","unstructured":"Frontera JA, Claassen J, Schmidt JM, et al. Prediction of symptomatic vasospasm after subarachnoid hemorrhage: the modified fisher scale. Neurosurgery. 2006;59:21\u20137.","journal-title":"Neurosurgery"},{"key":"2349_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jstrokecerebrovasdis.2020.105027","volume":"29","author":"JR Geraghty","year":"2020","unstructured":"Geraghty JR, Lara-Angulo MN, Spegar M, Reeh J, Testai FD. Severe cognitive impairment in aneurysmal subarachnoid hemorrhage: predictors and relationship to functional outcome. J Stroke Cerebrovasc Dis. 2020;29: 105027.","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"2349_CR17","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1186\/s13054-015-1036-0","volume":"19","author":"H Lantigua","year":"2015","unstructured":"Lantigua H, Ortega-Gutierrez S, Schmidt JM, et al. Subarachnoid hemorrhage: who dies, and why? Crit Care. 2015;19:309.","journal-title":"Crit Care"},{"key":"2349_CR18","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/gps.1402","volume":"21","author":"A Takeda","year":"2006","unstructured":"Takeda A, Loveman E, Clegg A, et al. A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer\u2019s disease. Int J Geriatr Psychiatry. 2006;21:17\u201328.","journal-title":"Int J Geriatr Psychiatry"},{"key":"2349_CR19","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1046\/j.1468-1331.2003.00677.x","volume":"10","author":"AF Kurz","year":"2003","unstructured":"Kurz AF, Erkinjuntti T, Small GW, Lilienfeld S, Damaraju CRV. Long-term safety and cognitive effects of galantamine in the treatment of probable vascular dementia or Alzheimer\u2019s disease with cerebrovascular disease. Euro J of Neurol. 2003;10:633\u201340.","journal-title":"Euro J of Neurol"},{"key":"2349_CR20","doi-asserted-by":"publisher","first-page":"777","DOI":"10.2165\/00002512-200320100-00006","volume":"20","author":"G Wilcock","year":"2003","unstructured":"Wilcock G, Howe I, Coles H, et al. A long-term comparison of galantamine and donepezil in the treatment of Alzheimer\u2019s disease. Drugs Aging. 2003;20:777\u201389.","journal-title":"Drugs Aging"},{"key":"2349_CR21","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1212\/01.wnl.0000303815.69777.26","volume":"70","author":"B Winblad","year":"2008","unstructured":"Winblad B, Gauthier S, Scinto L, et al. Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology. 2008;70:2024\u201335.","journal-title":"Neurology"},{"issue":"7","key":"2349_CR22","first-page":"635","volume":"72","author":"GJ Rinkel","year":"2009","unstructured":"Rinkel GJ, Wilde AA, Vandertop WP, Visser FC, van der Bilt IA, Hasan D. Impact of cardiac complications on outcome after aneurysmal subarachnoid haemorrhage. A Meta-Anal Neurol. 2009;72(7):635\u201342.","journal-title":"A Meta-Anal Neurol"},{"key":"2349_CR23","doi-asserted-by":"publisher","first-page":"5541","DOI":"10.1007\/s00415-022-11220-w","volume":"269","author":"MC Borutta","year":"2022","unstructured":"Borutta MC, Gerner ST, Moeser P, et al. Correlation between clinical severity and extent of autonomic cardiovascular impairment in the acute phase of subarachnoid hemorrhage. J Neurol. 2022;269:5541\u201352.","journal-title":"J Neurol"},{"key":"2349_CR24","doi-asserted-by":"publisher","first-page":"220","DOI":"10.5603\/CJ.a2014.0019","volume":"21","author":"MT Wybraniec","year":"2014","unstructured":"Wybraniec MT, Mizia-Stec K, Krzych \u0141. Neurocardiogenic injury in subarachnoid hemorrhage: a wide spectrum of catecholamin-mediated brain-heart interactions. Cardiol J. 2014;21:220\u20138.","journal-title":"Cardiol J"},{"key":"2349_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000157","volume":"6","author":"LY Park-Wyllie","year":"2009","unstructured":"Park-Wyllie LY, Mamdani MM, Li P, Gill SS, Laupacis A, Juurlink DN. Cholinesterase inhibitors and hospitalization for bradycardia: a population-based study. PLoS Med. 2009;6: e1000157.","journal-title":"PLoS Med"},{"key":"2349_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.wnsx.2024.100341","volume":"22","author":"J Abdelgadir","year":"2024","unstructured":"Abdelgadir J, Gelman J, Dutko L, Mehta V, Friedman A, Zomorodi A. Cognitive outcomes following aneurysmal subarachnoid hemorrhage: rehabilitation strategies. World Neurosurg: X. 2024;22: 100341.","journal-title":"World Neurosurg: X"},{"key":"2349_CR27","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1212\/01.wnl.0000234062.98062.e9","volume":"67","author":"JM Silver","year":"2006","unstructured":"Silver JM, Koumaras B, Chen M, et al. Effects of rivastigmine on cognitive function in patients with traumatic brain injury. Neurology. 2006;67:748\u201355.","journal-title":"Neurology"},{"key":"2349_CR28","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1080\/026990598122881","volume":"12","author":"GS Taverni","year":"1998","unstructured":"Taverni GS, Steven WLJP. Donepezil mediated memory improvement in traumatic brain injury during post acute rehabilitation. Brain Inj. 1998;12:77\u201380.","journal-title":"Brain Inj"},{"key":"2349_CR29","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1111\/j.1365-2710.2009.01056.x","volume":"34","author":"GK-C Wong","year":"2009","unstructured":"Wong GK-C, Wong R, Mok V, et al. Rivastigmine for cognitive impairment after spontaneous subarachnoid haemorrhage: a pilot study. J Clin Pharm Therapeut. 2009;34:657\u201363.","journal-title":"J Clin Pharm Therapeut"},{"key":"2349_CR30","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.jval.2024.11.006","volume":"28","author":"F Al Sayah","year":"2025","unstructured":"Al Sayah F, Jin X, Short H, McClure NS, Ohinmaa A, Johnson JA. A systematic literature review of important and meaningful differences in the EQ-5D index and visual analog scale scores. Value Health. 2025;28:470\u20136.","journal-title":"Value Health"},{"key":"2349_CR31","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1186\/s12955-020-01578-8","volume":"18","author":"X Hu","year":"2020","unstructured":"Hu X, Jing M, Zhang M, Yang P, Yan X. Responsiveness and minimal clinically important difference of the EQ-5D-5L in cervical intraepithelial neoplasia: a longitudinal study. Health Qual Life Outcomes. 2020;18:324.","journal-title":"Health Qual Life Outcomes"},{"key":"2349_CR32","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/S0140-6736(02)08267-3","volume":"359","author":"T Erkinjuntti","year":"2002","unstructured":"Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV. Efficacy of galantamine in probable vascular dementia and Alzheimer\u2019s disease combined with cerebrovascular disease: a randomised trial. Lancet. 2002;359:1283\u201390.","journal-title":"Lancet"},{"key":"2349_CR33","first-page":"391","volume":"10","author":"K Hager","year":"2014","unstructured":"Hager K, Baseman AS, Nye JS, et al. Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer\u2019s disease. Neuropsychiatr Dis Treat. 2014;10:391\u2013401.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"Suppl 1","key":"2349_CR34","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1159\/000051229","volume":"11","author":"R Blesa","year":"2000","unstructured":"Blesa R. Galantamine: therapeutic effects beyond cognition. Dement Geriatr Cogn Disord. 2000;11(Suppl 1):28\u201334.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"2349_CR35","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1176\/appi.ajp.161.3.532","volume":"161","author":"JL Cummings","year":"2004","unstructured":"Cummings JL, Schneider L, Tariot PN, Kershaw PR, Yuan W. Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer\u2019s disease. AJP. 2004;161:532\u20138.","journal-title":"AJP"},{"key":"2349_CR36","doi-asserted-by":"publisher","first-page":"e1838","DOI":"10.1212\/WNL.0000000000006506","volume":"91","author":"V Zietemann","year":"2018","unstructured":"Zietemann V, Georgakis MK, Dondaine T, et al. Early MoCA predicts long-term cognitive and functional outcome and mortality after stroke. Neurology. 2018;91:e1838\u201350.","journal-title":"Neurology"},{"key":"2349_CR37","doi-asserted-by":"publisher","first-page":"3161","DOI":"10.1161\/STROKEAHA.113.001126","volume":"44","author":"M Ali","year":"2013","unstructured":"Ali M, Fulton R, Quinn T, Brady M. VISTA Collaboration. How well do standard stroke outcome measures reflect quality of life? A retrospective analysis of clinical trial data. Stroke. 2013;44:3161\u20135.","journal-title":"Stroke"},{"key":"2349_CR38","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1089\/jpm.2023.0061","volume":"27","author":"VA Chang","year":"2024","unstructured":"Chang VA, Tirschwell DL, Becker KJ, Schubert GB, Longstreth WT, Creutzfeldt CJ. Associations between measures of disability and quality of life at three months after stroke. J Palliat Med. 2024;27:18\u201323.","journal-title":"J Palliat Med"},{"key":"2349_CR39","doi-asserted-by":"publisher","first-page":"748","DOI":"10.7150\/ijbs.24576","volume":"14","author":"C Ren","year":"2018","unstructured":"Ren C, Li X-H, Wang S-B, et al. Activation of central alpha 7 nicotinic acetylcholine receptor reverses suppressed immune function of T lymphocytes and protects against sepsis lethality. Int J Biol Sci. 2018;14:748\u201359.","journal-title":"Int J Biol Sci"},{"key":"2349_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241310943","volume":"24","author":"C-Z Chai","year":"2023","unstructured":"Chai C-Z, Ho U-C, Kuo L-T. Systemic inflammation after aneurysmal subarachnoid hemorrhage. Int J Mol Sci. 2023;24: 10943.","journal-title":"Int J Mol Sci"},{"key":"2349_CR41","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.17219\/acem\/176051","volume":"33","author":"Y Gao","year":"2024","unstructured":"Gao Y, Liu Y, Li Y. Safety and efficacy of acetylcholinesterase inhibitors for Alzheimer\u2019s disease: a systematic review and meta-analysis. Adv Clin Exp Med. 2024;33:1179\u201387.","journal-title":"Adv Clin Exp Med"},{"key":"2349_CR42","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.110.581975","author":"T Al-Khindi","year":"2010","unstructured":"Al-Khindi T, Macdonald RL, Schweizer TA. Cognitive and functional outcome after aneurysmal subarachnoid hemorrhage. Stroke. 2010. https:\/\/doi.org\/10.1161\/STROKEAHA.110.581975.","journal-title":"Stroke"},{"key":"2349_CR43","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1097\/00006123-200006000-00008","volume":"46","author":"BS Carter","year":"2000","unstructured":"Carter BS, Buckley D, Ferraro R, Rordorf G, Ogilvy CS. Factors associated with reintegration to normal living after subarachnoid hemorrhage. Neurosurgery. 2000;46:1326\u201333.","journal-title":"Neurosurgery"}],"container-title":["Neurocritical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12028-025-02349-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12028-025-02349-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12028-025-02349-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:03:54Z","timestamp":1764115434000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12028-025-02349-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,28]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2349"],"URL":"https:\/\/doi.org\/10.1007\/s12028-025-02349-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6198782\/v1","asserted-by":"object"}]},"ISSN":["1541-6933","1556-0961"],"issn-type":[{"value":"1541-6933","type":"print"},{"value":"1556-0961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,28]]},"assertion":[{"value":"17 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"HAC has received consultant fees from Grace Pharmaceuticals. Other authors have no conflict of interest to report.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study adhered to the ethical guidelines and was approved by the Committee for the Protection of Human Subjects at The University of Texas Health Science Center at Houston, Houston, Texas (institutional review board no. HSC\u2013MH-17\u20130452).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval\/informed consent"}}]}}